What Is Mounjaro (Tirzepatide)? — A Dual GIP/GLP-1 Obesity and Diabetes Drug
Lately we often hear names like 'Wegovy' and 'Mounjaro.' These are GLP-1 class prescription drugs originally developed to treat diabetes and obesity, and some of them have drawn attention—and become talking points—for their weight-loss effects. However, these drugs are not diet supplements you can casually buy and take; they are medications that absolutely require a physician's diagnosis and prescription. This article focuses on 'Mounjaro (tirzepatide)' and lays out what kind of drug it is and what you need to watch out for.
What kind of drug is Mounjaro?
Mounjaro (active ingredient tirzepatide) is a once-weekly subcutaneous injection developed by Eli Lilly. In Korea it has been approved and launched as a treatment for type 2 diabetes (2024–2025). In the United States, the same ingredient is also sold under a separate brand, 'Zepbound,' for an obesity (weight management) indication. In other words, even the same ingredient can have a different product name and approved scope depending on the country and indication.
What does GIP/GLP-1 'dual action' mean?
When we eat, our body secretes gut hormones called incretins that regulate blood sugar and appetite. Two of the most representative are GLP-1 and GIP. Whereas existing drugs like Wegovy and Ozempic act on the single GLP-1 pathway, tirzepatide is distinctive in that it is designed to act on both the GLP-1 and GIP receptors at the same time. Because of this 'dual action' structure, the fact that it does not have just a single mechanism of action sets it apart from other drugs.
How weight loss works
There are two core mechanisms by which this class of drugs affects body weight. First, they act on the brain's appetite center so you feel less hungry; second, they slow the rate at which food leaves the stomach (gastric emptying), keeping you feeling full for longer. As a result, total food intake decreases—it is not a drug that directly 'burns' fat.
How is it different from Wegovy, Ozempic, and Saxenda?
- Wegovy/Ozempic: the ingredient is semaglutide (Novo Nordisk), single GLP-1 action. Wegovy was launched in Korea with an obesity treatment indication (2024), a once-weekly subcutaneous injection.
- Saxenda: a GLP-1 drug line from the same Novo Nordisk family.
- Mounjaro: the ingredient is tirzepatide (Eli Lilly), dual GIP+GLP-1 action, a once-weekly injection. In Korea it was launched with a diabetes indication.
- In short, the 'manufacturer, ingredient, number of hormones acted on, and domestic approved indication' all differ. Which drug is right for you depends on the patient's condition, so a physician makes that judgment.
Has an 'oral GLP-1 obesity drug' come out?
People for whom injections are a burden show interest in oral GLP-1 drugs. Eli Lilly's orforglipron is known to be an oral candidate that has completed phase 3 trials and is in the approval/review stage. However, this is still an outlook at the development/approval-process stage and is before general launch. The specific launch timing, price, and domestic brand name, etc., have not been finalized and may change, so related information must be confirmed through the latest official announcements and news. (You should scrutinize the truth of information circulating online claiming that a specific product name has 'already been launched.')
Common side effects and risks to watch for
- The most common are gastrointestinal symptoms: nausea, vomiting, diarrhea, constipation, etc. They tend to appear more in the early stage when the dose is being increased.
- Rarely, pancreatitis, gallstones, etc., have been reported. If severe abdominal pain persists, you need medical attention immediately.
- Boxed warning (the strongest warning): because thyroid C-cell tumors were observed in animal (rodent) studies, it is contraindicated for those with a personal or family history of medullary thyroid carcinoma or a history of multiple endocrine neoplasia type 2 (MEN2).
- Beyond these, reactions can vary from person to person, so if abnormal symptoms occur, do not judge on your own—consult medical staff.
What you must know — it is a prescription drug
- These drugs are not diet supplements but prescription medications, prescribed at a physician's discretion when an indication, such as a BMI criterion, is met.
- Misuse for cosmetic or simple weight-loss purposes, overseas direct purchase, and arbitrary use of someone else's medication are dangerous from both safety and legal standpoints.
- Cases have been reported where, after stopping the drug, appetite returns and weight goes back up (rebound). Lifestyle management such as diet and exercise must go along with it.
- If prescribed as non-reimbursed (out-of-pocket), the cost can be considerably high; whether it is covered and its price differ depending on the time and the indication.
In the end, these drugs are a 'tool' that reduces appetite and lowers intake—they are not magic that replaces lifestyle habits. Starting, stopping, and changing treatment must all be decided together with medical staff.
Notice (disclaimer)
This article is for general medical-information reference only and does not replace diagnosis or prescription. Decisions on whether the drug is suitable, and on starting, stopping, or changing the dose, must be made in consultation with a physician or pharmacist. A drug's indication, approved scope, reimbursement status, price, etc., can change depending on the time and country, so confirm the latest information through official sources such as the Ministry of Food and Drug Safety and through medical consultation. If you suspect emergency symptoms (severe abdominal pain, difficulty breathing, allergic reactions, etc.), please visit a medical institution immediately.